Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...

HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Healthcare distributor and services company McKesson (NYSE:MCK) will be reporting results this Wednesday after market close.

Despite the indication of a potential risk, people who receive abnormal results on blood-based colorectal screening tests commonly do not receive the follow-up colonoscopy.

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...

James Van Der Beek, whose net worth is $6 million, as per Celebrity Net Worth, has partnered with Guardant Health to raise ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute ...

Guardant Health thinks around 700,000 patients in the U.S. could eventually benefit from advanced-stage cancer screening, which would drive up sales to around $6 billion annually.